AU2006311729A1 - Benzimidazole derivatives as gyrase inhibitors - Google Patents

Benzimidazole derivatives as gyrase inhibitors Download PDF

Info

Publication number
AU2006311729A1
AU2006311729A1 AU2006311729A AU2006311729A AU2006311729A1 AU 2006311729 A1 AU2006311729 A1 AU 2006311729A1 AU 2006311729 A AU2006311729 A AU 2006311729A AU 2006311729 A AU2006311729 A AU 2006311729A AU 2006311729 A1 AU2006311729 A1 AU 2006311729A1
Authority
AU
Australia
Prior art keywords
ring
aliphatic
nitrogen
membered
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006311729A
Other languages
English (en)
Inventor
Paul Charifson
David Deininger
Joseph Drumm
Anne-Laure Grillot
Arnaud Letiran
Yusheng Liao
Emanuele Perola
Steven Ronkin
Dean Stamos
Tiansheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2006311729A1 publication Critical patent/AU2006311729A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006311729A 2005-11-07 2006-11-06 Benzimidazole derivatives as gyrase inhibitors Abandoned AU2006311729A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73413905P 2005-11-07 2005-11-07
US60/734,139 2005-11-07
PCT/US2006/043269 WO2007056330A1 (en) 2005-11-07 2006-11-06 Benzimidazole derivatives as gyrase inhibitors

Publications (1)

Publication Number Publication Date
AU2006311729A1 true AU2006311729A1 (en) 2007-05-18

Family

ID=37894258

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006311729A Abandoned AU2006311729A1 (en) 2005-11-07 2006-11-06 Benzimidazole derivatives as gyrase inhibitors

Country Status (7)

Country Link
US (1) US8394803B2 (cg-RX-API-DMAC10.html)
EP (1) EP1948635A1 (cg-RX-API-DMAC10.html)
JP (1) JP2009514894A (cg-RX-API-DMAC10.html)
CN (1) CN101321744A (cg-RX-API-DMAC10.html)
AU (1) AU2006311729A1 (cg-RX-API-DMAC10.html)
CA (1) CA2626685A1 (cg-RX-API-DMAC10.html)
WO (1) WO2007056330A1 (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR069599A1 (es) 2007-12-07 2010-02-03 Vertex Pharma Forma cristalina de 1- etil-1-3-(5-(5- fluoropiridin -3-il)-7- (pirimidin-2-il)-1h-benzo (d) imidazol -2-il) urea
WO2010027583A1 (en) 2008-09-03 2010-03-11 Universal Display Corporation Phosphorescent materials
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2010111058A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US9221765B2 (en) 2009-06-10 2015-12-29 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
EP2552893B1 (en) 2010-03-31 2014-10-29 Actelion Pharmaceuticals Ltd. Antibacterial isoquinolin-3-ylurea derivatives
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
CA2801274C (en) 2010-06-01 2021-06-15 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151617A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
KR101882172B1 (ko) * 2011-01-14 2018-07-26 스페로 트리넴, 인코포레이티드 자이라제 및 토포이소머라제 ⅳ 억제제의 제조방법
MX341342B (es) 2011-01-14 2016-08-17 Vertex Pharma Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
JP6085829B2 (ja) 2011-01-14 2017-03-01 スペロ トリネム, インコーポレイテッド ピリミジンジャイレースおよびトポイソメラーゼiv阻害剤
US8481552B2 (en) 2011-01-14 2013-07-09 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-YL]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-YL]urea
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
ES2576298T3 (es) * 2011-06-20 2016-07-06 Vertex Pharmaceuticals Incorporated Ésteres de fosfato de inhibidores de girasa y topoisomerasa
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
SG11201606332PA (en) 2014-02-03 2016-09-29 Spero Gyrase Inc Antibacterial combinations comprising polymyxin
CN104945329B (zh) * 2014-03-24 2017-09-01 中国医学科学院医药生物技术研究所 抗结核药物
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
RU2019133662A (ru) 2017-03-24 2021-04-26 Тайсо Фармасьютикал Ко., Лтд. Производное 2(1h)-хинолинона
JP7730803B2 (ja) 2019-07-17 2025-08-28 サミット (オックスフォード) リミティド リジニラゾールの調製方法およびその結晶形態
CN111658646B (zh) * 2020-06-28 2021-03-02 河南工业大学 2,6-双(2-苯并咪唑基)吡啶在制备耐碳青霉烯类铜绿假单胞菌感染药物中的应用
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
US12220421B2 (en) 2021-09-09 2025-02-11 The Boards Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Inhibitors of C. difficile spore germination

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL362691A1 (en) 2000-12-15 2004-11-02 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
AU2003245442B2 (en) 2002-06-13 2009-02-05 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase IV inhibitors for the treatment of bacterial infections
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof

Also Published As

Publication number Publication date
CN101321744A (zh) 2008-12-10
CA2626685A1 (en) 2007-05-18
US8394803B2 (en) 2013-03-12
US20130030004A1 (en) 2013-01-31
JP2009514894A (ja) 2009-04-09
EP1948635A1 (en) 2008-07-30
WO2007056330A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
US8394803B2 (en) Gyrase inhibitors and uses thereof
CA2513463C (en) Gyrase inhibitors and uses thereof
CA2433197C (en) Gyrase inhibitors and uses thereof
KR101052433B1 (ko) 자이라제 및/또는 토포이소머라제 ⅳ 억제제로서의 2-우레이도-6-헤테로아릴-3h-벤조이미다졸-4-카복실산 유도체 및 이를 포함하는 세균 감염 치료용 약제학적 조성물
US8268811B2 (en) Thiazoles and pyrazoles useful as kinase inhibitors
US7659283B2 (en) Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
US8563576B2 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
US20110060013A1 (en) Thiazoles and pyrazoles useful as kinase inhibitors
NZ555566A (en) Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US20120165368A1 (en) Pyrazolopyridine kinase inhibitors
CA2672612A1 (en) Compounds useful as protein kinase inhibitors
NZ575346A (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
CA2681516A1 (en) Compounds useful as inhibitors of janus kinases
EP1789419A1 (en) Gyrase inhibitors and uses thereof
NZ576950A (en) Compounds useful as protein kinase inhibitors, particulary PLK1 protein kinases
US20110081316A1 (en) Pyrazole inhibitors of phosphatidylinositol 3-kinase
HK1124589A (en) Benzimidazole derivatives as gyrase inhibitors
HK1145497A (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period